SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs
Sheila Connelly
Microorganisms
View PDFchevron_right
Orally administered b-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile
Curtis Donskey
2008
View PDFchevron_right
Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies
barbara lopez
Clinical drug investigation, 2016
View PDFchevron_right
Oral Beta-Lactamase Protects the Canine Gut Microbiome from Oral Amoxicillin-Mediated Damage
Sheila Connelly
Microorganisms
View PDFchevron_right
Orally administered targeted recombinant beta-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing …
marja heikkilä
Antimicrobial agents …, 2004
View PDFchevron_right
Orally Administered Targeted Recombinant Beta-Lactamase Prevents Ampicillin-Induced Selective Pressure on the Gut Microbiota: a Novel Approach to Reducing Antimicrobial Resistance
Curtis Donskey
Antimicrobial Agents and Chemotherapy, 2004
View PDFchevron_right
Beta-lactamase inhibitors from laboratory to clinic
Karen Bush
Clinical Microbiology Reviews, 1988
View PDFchevron_right
Current developments in lantibiotic discovery for treatingClostridium difficileinfection
Stephanie Sandiford
Expert Opinion on Drug Discovery, 2018
View PDFchevron_right
P1A Recombinant β-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin
Silja Mentula
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice
Michael Pultz
Antimicrobial agents and chemotherapy, 2014
View PDFchevron_right
Enzymic degradation of a β-lactam antibiotic, ampicillin, in the gut: a novel treatment modality
K. Vaali
Journal of …, 2003
View PDFchevron_right
Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis
Sheila Connelly
Microorganisms
View PDFchevron_right
A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity
Curtis Donskey
mBio, 2015
View PDFchevron_right
Ribaxamase, an orally administered β-lactamase, protects the gut microbiome in patients treated with ceftriaxone
Sheila Connelly
Journal of translational science, 2020
View PDFchevron_right
P1A Recombinant -Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin
Tuula Heinonen, Curtis Donskey
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
Next-Generation Probiotics Targeting Clostridium difficile through Precursor-Directed Antimicrobial Biosynthesis
Jennifer Auchtung
Infection and Immunity
View PDFchevron_right
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
christian carter
Antimicrobial agents and chemotherapy, 2017
View PDFchevron_right
β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs
Concepcion Gonzalez-Bello
Journal of Medicinal Chemistry, 2019
View PDFchevron_right
Intrinsic Class D β-Lactamases of Clostridium difficile
Clyde Smith
mBio, 2018
View PDFchevron_right
Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes
Steven Boyd
Journal of Medicinal Chemistry, 2021
View PDFchevron_right
Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents
Mark Blaskovich
Journal of medicinal chemistry, 2015
View PDFchevron_right
Controlling resistant bacteria with a novel class of β-lactamase inhibitor peptides: from rational design to in vivo analyses
Ludovico Migliolo
Scientific Reports, 2014
View PDFchevron_right
Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance
Richard Watkins
Frontiers in Microbiology, 2013
View PDFchevron_right
The Spread of 𝛽-Lactamases and Extended Spectrum 𝛽-Lactamase Enzymes among Bacteria: A Threat to Effective Health Care Delivery
Isah Abdullahi
EAS Journal of Biotechnology and Genetics, 2022
View PDFchevron_right
In Vitro and In Vivo Properties of BAL30376, a β-Lactam and Dual β-Lactamase Inhibitor Combination with Enhanced Activity against Gram-Negative Bacilli That Express Multiple β-Lactamases
carlos dantier
Antimicrobial Agents and Chemotherapy, 2011
View PDFchevron_right
Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?
Sandhya Nagarakanti
Infection and Drug Resistance
View PDFchevron_right
TEM-80, a Novel Inhibitor-Resistant -Lactamase in a Clinical Isolate of Enterobacter cloacae
Professeur Labia
Antimicrobial Agents and Chemotherapy, 2002
View PDFchevron_right
Colonization Resistance of the Gut Microbiota against Clostridium difficile
Amparo Latorre
Antibiotics, 2015
View PDFchevron_right
β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
David Paterson
The Lancet. Infectious diseases, 2015
View PDFchevron_right
Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice
Fernanda Schreiber
PLoS Pathogens
View PDFchevron_right